Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING
WeWork Putting the Brakes on China Push: Report
Tencent-Backed E-Book Platform Partners With Disney for ‘Star Wars’ Project
Tesla’s China Plant Is Hooked Up to State Grid Power Supply
LATEST
Tencent-Backed E-Book Platform Partners With Disney for ‘Star Wars’ Project
iQiyi Looks to AI to Force-Feed Ads to Viewers
Popular Walking App Accused of Financial Fraud
WeWork Putting the Brakes on China Push: Report
‘No New Progress’ on Zotye Joint-Venture With Ford
Qutoutiao’s Online Literature Unit Gets $100 Million Windfall
NBA’s China Crisis Has Already Caused ‘Substantial’ Losses, Commissioner Says
Northern China Aims to Curb Toxic Air Pollution by 4% This Winter
China’s Economic Growth Dips to New Nearly Three-Decade Low
Tesla’s China Plant Is Hooked Up to State Grid Power Supply
Didi Pushes Further Into Latin America With Eye on Costa Rica
Homeowners Demand Refunds After Developer Cuts Prices
Controversial WeChat Public Account Operator Eyes High-Tech Board IPO
Burgeoning Online Marketplace in Crisis After Luring New Shoppers With Merchants’ Money
Huawei Posts Strong Revenue Growth Despite U.S. Export Ban
Ant Financial Seeks Loan of as Much as $3.5 Billion at Lower Rate
China Freezes Some Social Media, Mobile Payment Accounts in Myanmar Cross-Border Fraud Crackdown
Popular Translation App Youdao Downsizes New York IPO
Popular Alibaba-Backed Social E-Commerce App Returns After Months-Long Absence
Cheap-Phone Maker Realme Eyes Upscale Turn With Pricey New Handset
Chinese DNA Sequencing Firm BGI Faces Legal Battle with Illumina

By Wang Luyao and Han Wei / May 24, 2019 02:59 AM / Business & Tech

Photo: VCG

Photo: VCG

Chinese genomics giant BGI Group said it is prepared in the face of rising legal disputes in Europe and may resort to counterclaims to fight patent infringement allegations.

BGI is “actively responding to recent patent disputes and will take corresponding legal actions,” BGI said in a statement to Caixin Thursday, adding that it “will not rule out the use of legal weapons such as counterclaims to protect its legal rights.”

BGI’s subsidiary BGI Europe was sued by Illumina Inc. in Denmark on alleged patent infringement last week. The complaint alleged BGI's sequencing products and related sequencing chemistry reagents infringe on Illumina's European patent.

The case followed another infringement suit filed by Illumina in Germany against another BGI subsidiary, Latvia MGI Tech, in March.

In the statement, BGI said it is confident in its own technology, which cost billions of yuan to develop and “broke the market monopoly in the upstream genome sequencing market.”

When interviewed by Caixin earlier this month on whether Illumina will file more suits against BGI outside Europe, the company’s Chief Commercial Officer Mark Van Oene said Illumina will continue pursuing patent protection, without elaborating.

Established in 1999, BGI was a client of Illumina’s sequencing equipment but has started to develop its own devices after purchasing U.S. genomics company Complete Genomics in 2012.

Related: BGI Genomics’ Profits Slip As Questions Linger About Its Services


Share this article
Open WeChat and scan the QR code